More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

Sanofi has named Olivier Brandicourt, current chairman of the board of management of Bayer Healthcare, as the company's new CEO. What is in store for Sanofi and Bayer? DCAT Value Chain Insights (VCI) examines the companies' strategies, challenges,...
DCAT Value Chain Insights

Parenteral drugs, particularly generic specialty injectables, are expected to see strong growth in the long-term. In the wake of Pfizer's proposed $17 billion acquisition of Hospira, what will be the implications for the global injectables market?...
DCAT Value Chain Insights

Venture capital funding is an important source for financing drug development and pharmaceutical innovation. So which therapeutic areas receive the greatest funding, and which areas may trail? DCAT Value Chain Insights (VCI) shares results from a...
DCAT Value Chain Insights

Sanofi, GlaxoSmithKline, and AstraZeneca released their earnings last week. How did these companies fare, and how did the sector leaders in specialty pharmaceuticals and generics as well as biologics perform? DCAT Value Chain Insights (VCI)...
DCAT Value Chain Insights

Pfizer's proposed $17 billion acquisition of Hospira will add to Pfizer's Global Established Pharmaceutical business, including biosimilars. What are the implications for Pfizer on both a product and manufacturing basis? DCAT Value Chain Insights...
DCAT Value Chain Insights

Earnings season has begun with many of the pharmaceutical majors reporting 2014 results. So how did companies fare and what is their outlook for 2015? DCAT Value Chain Insights (VCI) examines 2014 performance and what lies ahead.  Many of the...
DCAT Value Chain Insights

The success of the innovator drug market is critical not only for pharmaceutical companies, but also for their manufacturing partners and suppliers. Oncology, the largest therapeutic category in the global pharmaceutical market, offers great...
DCAT Value Chain Insights

What is the working relationship between the FDA and industry? Have expectations changed, and if so, how? A recent analysis by the PwC Health Research Institute examines how pharmaceutical company executives view the FDA in a changing healthcare...
DCAT Value Chain Insights

How are the fundamentals for the market for custom synthesis? DCAT Value Chain Insights (VCI) examines the key factors shaping the market and recent activity among fine-chemical producers and contract manufacturers. The collective performance of...